LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

CareDx Inc

Cerrado

SectorSalud

19.54 2.25

Resumen

Variación precio

24h

Actual

Mínimo

19.44

Máximo

19.9

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.773

121.746

Margen de beneficio

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-8.3% downside

Dividendos

By Dow Jones

Próximas Ganancias

24 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

288M

1.1B

Apertura anterior

17.29

Cierre anterior

19.54

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

48 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 feb 2026, 23:21 UTC

Adquisiciones, fusiones, absorciones

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb 2026, 23:40 UTC

Charlas de Mercado

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb 2026, 23:06 UTC

Ganancias

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb 2026, 23:04 UTC

Ganancias

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb 2026, 23:01 UTC

Ganancias

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb 2026, 22:52 UTC

Adquisiciones, fusiones, absorciones

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb 2026, 22:14 UTC

Adquisiciones, fusiones, absorciones

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb 2026, 22:14 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb 2026, 20:48 UTC

Ganancias

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb 2026, 20:47 UTC

Ganancias

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb 2026, 20:46 UTC

Ganancias

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb 2026, 20:45 UTC

Ganancias

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb 2026, 20:44 UTC

Ganancias

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb 2026, 20:44 UTC

Ganancias

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb 2026, 20:43 UTC

Ganancias

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb 2026, 20:42 UTC

Ganancias

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb 2026, 20:42 UTC

Ganancias

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb 2026, 20:41 UTC

Ganancias

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb 2026, 20:40 UTC

Ganancias

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb 2026, 20:40 UTC

Ganancias

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb 2026, 20:39 UTC

Ganancias

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparación entre iguales

Cambio de precio

CareDx Inc Esperado

Precio Objetivo

By TipRanks

-8.3% caída

Estimación a 12 meses

Media 18 USD  -8.3%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

0

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

48 / 351 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat